Plain-English translation of NCT06510660 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new immunotherapy drug called to treat advanced esophageal cancer that cannot be surgically removed. Depending on a specific biomarker in your tumor, you'll receive this medication either on its own or combined with chemotherapy drugs, followed by chemotherapy paired with radiation therapy. The goal is to see if this approach can shrink or eliminate the cancer.
Currently, patients with advanced esophageal cancer that cannot be operated on have limited treatment options. Researchers believe combining this new immunotherapy medication with standard chemotherapy and radiation may work better than current treatments alone to help more patients survive longer.
You likely qualify if…
You likely don't qualify if…
Your participation lasts about 11 weeks total. First, you'll receive the medication intravenously (by IV) every 3 weeks for 6 weeks—either the new drug alone or combined with chemotherapy, depending on your tumor's biomarker. After that, you'll undergo 5 weeks of concurrent chemoradiotherapy, receiving chemotherapy once weekly while also receiving daily radiation therapy. You'll have regular clinic visits for blood tests, imaging, and monitoring of side effects throughout the treatment period.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Fujian Medical University Union Hospital
Collaborators
Sun Yat-Sen University Cancer Center
Enrollment target
~48 participants
Started
April 2024
Primary completion
December 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 70 Years
Last updated on clinicaltrials.gov in September 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Yong Yang, Doctor
Fujian Medical University Union Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.